Dr. Reddy's Laboratories Limited has entered into a Settlement Agreement with Indivior Inc. ("Indivior Inc.") and Indivior UK Limited, ("Indivior UK," and together with Indivior Inc., "Indivior") and Aquestive Therapeutics, Inc. ("Aquestive"). Pursuant to the agreement, the Company will receive payments totalling USD 72 million by March 31, 2024. The said agreement resolves all claims between the parties relating to the Company's generic buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg dosages, including Indivior's and Aquestive's patent infringement allegations and the Company's antitrust counterclaims. As part of the settlement, the underlying litigation will be dismissed.
Shares of Dr. Reddy's Laboratories Limited was last trading in BSE at Rs. 4308.75 as compared to the previous close of Rs. 4296.20. The total number of shares traded during the day was 6881 in over 1656 trades.
The stock hit an intraday high of Rs. 4370.00 and intraday low of 4292.35. The net turnover during the day was Rs. 29731116.00.